DLD Asset Management’s Aspire Biopharma ASBP Stock Holding History

DLD Asset Management’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-39	Closed	-$480K	–	142
2022 Q4	$480K	Buy	39 +3	+8%	+$36.7K	0.04%	111
2022 Q3	$439K	Hold	36	–	–	0.03%	140
2022 Q2	$432K	Buy	+36	New	+$431K	0.03%	164

Other funds holding ASBP

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

DLD Asset Management's ASBP Position: Q1 2023 in Review

DLD Asset Management sold out of Aspire Biopharma (ASBP) in Q1 2023, closing a stake of 39 shares — an estimated $480K sold.

DLD Asset Management first reported a position in ASBP in Q2 2022 and held it in 3 quarters. The position peaked at $480K in Q4 2022. 57 funds tracked by Wall St. Rank hold ASBP as of Q1 2023.

DLD Asset Management reported no remaining Aspire Biopharma position as of Q1 2023 after selling out during the quarter.
DLD Asset Management sold 39 Aspire Biopharma shares in Q1 2023, an estimated $480K.
DLD Asset Management first reported a position in Aspire Biopharma in Q2 2022 and held it in 3 quarters.
DLD Asset Management's Aspire Biopharma position peaked at $480K in Q4 2022.
57 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2023.

Based on DLD Asset Management's 13F filing for Q1 2023, filed 15 May 2023.